论文部分内容阅读
目的观察Graves病患者外周血辅助性T细胞(Th细胞)表面CCR5和CD30的表达,探讨Th1/Th2细胞失衡在Graves病患者发病中的作用。方法选择89例Graves病患者,将其分为Graves病未治疗组(Graves病组,31例)、Graves病甲巯咪唑治疗组(甲巯咪唑组,30例)和Graves病13Ⅰ1治疗组(13Ⅰ1组,28例),另选择35例健康者作为对照组。采用流式细胞技术检测4组血清甲状腺相关指标及外周血淋巴细胞中CCR5及CD30的表达量,以此作为反映Th1/Th2免疫应答强度的指标。结果Graves病组患者CD30表达量高于对照组,CCR5/CD30低于对照组,差异有统计学意义(P<0.01);甲巯咪唑组和13Ⅰ1组患者CCR5/CD30高于Graves病组,差异有统计学意义(P<0.05),但与对照组比较差异无统计学意义(P>0.05)。相关分析显示,CD30表达量与促甲状腺素受体抗体(TRAb)水平呈正相关(r=0.38,P<0.01),CCR5/CD30与TRAb水平呈负相关(r=-0.33,P<0.01),CCR5水平与TRAb水平无相关性(r=-0.14,P>0.05)。结论Graves病患者Th细胞表面CD30表达明显增加,CCR5/CD30比值降低,提示Th1/Th2细胞失衡参与了Graves病的免疫调节过程;而甲巯咪唑和13Ⅰ1治疗能缓解Graves病患者Th1/Th2细胞失衡。
Objective To observe the expression of CCR5 and CD30 on peripheral blood T helper cells (Th cells) in patients with Graves ’disease and to explore the role of Th1 / Th2 cell imbalance in the pathogenesis of Graves’ disease. Methods Ninety-nine patients with Graves’ disease were divided into two groups: Graves disease group (31 cases), Graves disease methimazole group (30 cases) and Graves disease group 13Ⅰ1 (13Ⅰ1) Group, 28 cases), another 35 healthy people as control group. Flow cytometry was used to detect the serum thyroid-related indexes and the expression of CCR5 and CD30 in peripheral blood lymphocytes, which were used as an index to reflect the Th1 / Th2 immune response intensity. Results The expression of CD30 in Graves disease group was higher than that in control group, and CCR5 / CD30 was lower than that in control group (P <0.01). CCR5 / CD30 in methimazole group and 13Ⅰ1 group was higher than that in Graves’ disease group (P <0.05), but there was no significant difference with the control group (P> 0.05). Correlation analysis showed that CD30 expression was positively correlated with TRAb level (r = 0.38, P <0.01), and CCR5 / CD30 was negatively correlated with TRAb level (r = -0.33, P <0.01) There was no correlation between CCR5 level and TRAb level (r = -0.14, P> 0.05). Conclusions The expression of CD30 on Th cell surface and the ratio of CCR5 / CD30 in Graves’ disease patients are significantly decreased, suggesting that the imbalance of Th1 / Th2 cells is involved in the immune regulation of Graves’ disease. Thiazolidine and 13I1 treatment can relieve the imbalance of Th1 / Th2 cells in patients with Graves’ disease .